DOPAMINERGIC MECHANISMS IN THE PATHOGENESIS OF SCHIZOPHRENIA

被引:145
作者
GOLDSTEIN, M
DEUTCH, AY
机构
[1] NYU, SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10016 USA
[2] YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06510 USA
[3] DEPT VET AFFAIRS MED CTR, West Haven, CT 06516 USA
关键词
DOPAMINE; ANTIPSYCHOTIC DRUGS; CHOLECYSTOKININ; CORTEX; EXCITATORY AMINO ACIDS; NEUROTENSIN; DOPAMINE RECEPTORS;
D O I
10.1096/fasebj.6.7.1348713
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The dopamine hypothesis of schizophrenia has been the dominant theoretical construction guiding research and treatment of the schizophrenic disorders over the past generation. This hypothesis, in its simplest guise, posits the presence of a functional alteration in central dopaminergic systems in the brains of schizophrenic patients. Recent findings have resulted in a greater understanding of the complexity of the central dopaminergic systems and have led to revisions of the hypothesis of a simple functional hyperactivity of central dopaminergic systems. These recent data suggest that there may be regionally restricted changes in the function of the mesotelencephalic dopamine system, and that these changes may be in opposite directions. Such changes may be associated with dysfunctions of interactions between distinct dopaminergic terminal field regions, and may be subserved by functional derangements in other transmitter systems or reflect regionally restricted changes in expression or function of distinct dopamine receptors or catecholamine synthetic enzymes. A recent FASEB symposium reviewed new advances in molecular biology, biochemistry, pharmacology, anatomy, and systems neuroscience as they relate to schizophrenia, and discussed the implications of these data for guiding future research and treatment strategies.
引用
收藏
页码:2413 / 2421
页数:9
相关论文
共 67 条
  • [31] CHEMICAL ANATOMY OF THE BRAIN
    HOKFELT, T
    JOHANSSON, O
    GOLDSTEIN, M
    [J]. SCIENCE, 1984, 225 (4668) : 1326 - 1334
  • [32] JARVIE KR, 1988, MOL PHARMACOL, V34, P91
  • [33] JELLINGER K, 1985, PATHOCHEMICAL MARKER, P1
  • [34] KIRCH DG, 1986, HDB SCHIZOPHRENIA, V1, P325
  • [35] LEE KY, 1990, FASEB J, pA601
  • [36] LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993
  • [37] PHENOTYPICAL CHARACTERIZATION OF THE RAT STRIATAL NEURONS EXPRESSING THE D1 DOPAMINE RECEPTOR GENE
    LEMOINE, C
    NORMAND, E
    BLOCH, B
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (10) : 4205 - 4209
  • [38] SOLUBILIZATION AND CHARACTERIZATION OF STRIATAL DOPAMINE-RECEPTORS
    LEW, JY
    GOLDSTEIN, M
    [J]. JOURNAL OF NEUROCHEMISTRY, 1984, 42 (05) : 1298 - 1305
  • [39] REGULATION AND MOLECULAR CHARACTERIZATION OF DOPAMINE-D2 RECEPTORS IN A PROLACTIN-SECRETING 7315A ANTERIOR-PITUITARY TUMOR
    LEW, JY
    ZAWADZKA, H
    FEIGENBLUM, D
    TANG, D
    FILER, D
    BENEDETTO, P
    GOLDSTEIN, M
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1990, 188 (06): : 329 - 334
  • [40] LONART G, 1991, J PHARMACOL EXP THER, V256, P1132